Search Results

Ensysce Biosciences, Inc. today announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product.

Ensysce Biosciences, Inc. today announced Dr. Dolly Jacob, Director Integrated Development Services of Quotient Sciences, will present the collaborative work of Ensysce and Quotient Sciences in a poster.

Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had signed an agreement with Quotient Sciences, a drug development and manufacturing accelerator, for the delivery of its Sunlight Trial.

Quotient Limited announced that it has given formal notice to the Nasdaq Stock Market LLC of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market.

Ensysce Biosciences, Inc. today announced that the company will be providing a poster presentation at the upcoming CRS (Controlled Release Society) 2023 Annual Meeting & Expo.

Quotient Limited announced an agreement with Theradiag, a market leader in autoimmune disease testing and pioneer in theranostics, under which the two companies will partner to advance autoimmune diagnostics by leveraging Quotient’s MosaiQ platform.

Quotient Limited, a commercial-stage diagnostics company, announced that it will effect a one-for-40 reverse stock split of its ordinary shares, nil par value that will become effective on November 2, 2022 at 5:01 p.m. Eastern Time, after the close of trading on The Nasdaq Global Market.

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, announced it was selected by the World Economic Forum to join their New Champions Community.

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with InfYnity Biomarkers, an R&D firm dedicated to utilizing biomarkers for the management of infectious and immunology diseases, under which the two companies will partner to advance the safety and effectiveness of infectious disease testing by leveraging Quotient’s MosaiQ solution.